A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

European Urology

Volumn 52, Issue 5, 2007, Pages 1398-1406

  Ojea, Antonio ^a   Nogueira, José Luís ^a   Solsona, Eduardo ^b   Flores, Nicolás ^c   Gómez, Jesus Maria Fernandez ^d   Molina, Jesús Rodríguez ^e   Chantada, Venancio ^f   Camacho, José Emilio ^g   Piñeiro, Luís Martínez ^h   Rodríguez, Rafael Hernandez ⁱ   Isorna, Santiago ^j   Blas, Miguel ^k   Martínez Piñeiro, José A ^l   Madero, Rosario ^h  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d Servicio de Geriatría   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g Hospital SAS Jerez de la Frontera   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^j Hospital Nuestra Senora del Pino   (Spain)

^k HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^l Clinica La Luz   (Spain)

more..

Author keywords

Adjuvant therapy; Bacillus Calmette Guerin; Bladder cancer; Mitomycin C

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; BIOPSY; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; CYSTOSCOPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MITOMYCIN; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34548859502     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.04.062     Document Type: Article

References (19)

1. Lum B.L., and Torti F.M. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 83 (1991) 682-694
2. Lamm D.L., van der Meijden P.M., Morales A., et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147 (1992) 596-600
3. Lamm D.L., Riggs D.R., Traynelis C.L., and Nseyo U.O. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153 (1995) 1444-1450
4. Shelley M.D., Wilt T.J., Coles B., et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
5. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
6. Pagano F., Bassi P., Milani C., Meneghini A., Maruzzi D., and Garbeglio A. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?. J Urol 146 (1991) 32-35
7. Morales A., Nickel C., and Wilson J.W.L. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 147 (1992) 1256-1258
8. Martínez-Pineiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
9. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1245
10. Guy L., Savareux L., Molinie V., et al. Should bladder biopsies be performed routinely after bacillus Calmette-Guerin treatment for high-risk superficial transitional cell cancer of the bladder?. Eur Urol 50 (2006) 516-520
11. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790-797
12. Witjes J.A., Melissen D.O., and Kiemeney L.A. Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol 49 (2006) 478-484
13. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
14. Joudi F.N., Smith B.J., O'Donnell M.A., et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1639
15. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 56 (2004) 65-72
16. Mack D., and Frick J. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology 45 (1995) 958-961
17. Mack D., Holtl W., Bassi P., et al., European Organisation for Research and Treatment of Cancer Genitourinary Group. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 165 (2001) 401-403
18. Kumar A., Dubey D., Bansal P., Mandhani A., and Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 168 (2002) 2232-2235
19. Cheng C.W., Ng M.T., Chan S.Y., and Sun W.H. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. ANZ J Surg 74 (2004) 569-572